* Most popular articles from last 24 hours
-
Wednesday, November 11th
7 Dividend Stocks to Prove Buy-and-Hold Isn't Dead
-
Friday, November 13th
Law Firms Going After Hemispherx
-
IMS Health Merger Likely to Close
-
Tuesday, November 3rd
Dendreon's Provenge Looks Likely to Be Approved in Mid-2010
-
Wednesday, November 11th
Chelsea Therapeutics: There Are Safer Rebound Plays
-
Monday, November 2nd
3 Holiday Stocking Stuffers for Big Gains in 2010
-
Monday, November 9th
Three Core Biotech Holdings: Isis, Ligand and Vical
-
Tuesday, November 3rd
Four Biotech Stocks to Play the Sector Pullback
-
Tuesday, November 10th
Cel-Sci: Good News Could Lead to Long-Term Growth
-
Thursday, November 5th
Hemispherx Biopharma Could Become a Nice Rebound Story
-
Wednesday, November 11th
Access Pharma Looking for Smooth U.S. MuGard Launch in 2010
-
Baupost Initiates Enzon Position, Ups ViaSat Stake
-
Lexicon Pharmaceuticals: Stuck in Phase II?
-
Sunday, October 25th
Spectrum Pharma: Zevalin Has Blockbuster Potential
-
Wednesday, November 4th
CDC Sticking with 'Tried and True' Methods for Flu Vaccines
-
Tuesday, November 3rd
Titan Pharma Stock Remains Primed to Spike
-
Monday, November 9th
Insmed Still Looks Very Undervalued